Publikationen

1. Stern D.M., Drillings M., Kisiel W., Nawroth P., Nossel H.L., LaGamma K.S.: Activation of factor IX bound to cultured bovine aortic endothelial cells. Proc. Natl. Acad. Sci. USA 81:913-917, 1984.
2. Stern D.M., Nawroth P., Kisiel W., Handley D., Drillings M., Bartos J.: A coagulation pathway on bovine aortic segments leading to generation of factor Xa and thrombin. J. Clin. Invest. 74:1910-1921, 1984.
3. Stern D.M., Nawroth P., Marcum J., Handley D., Kisiel W., Rosenberg R., Stern K.: Interaction of antithrombin III with bovine aortic segments. J. Clin. Invest. 75:272-277, 1985.
4. Stern D.M., Nawroth P., Handley D., Kisiel W.: An endothelial cell dependent pathway of coagulation. Proc. Natl. Acad. Sci. USA 82:2523-2527, 1985.
5. Stern D.M., Nawroth P.P., Kisiel W., Vehar G., Esmon C.T.: The binding of factor IXa to cultured bovine aortic endothelial cells: Induction of a specific site in the presence of factors VIII and X.  J. Biol. Chem. 260:6717-6722, 1985.
6. Nawroth P., MaCarthy D., Kisiel W., Handley D., Stern D.M.: Cellular processing of bovine factors X and Xa by cultured bovine aortic endothelial cells. J. Exp. Med. 162:559-572, 1985.
7. Stern D.M., Bank I., Nawroth P.P., Cassimeris J., Kisiel W., Fenton J.W.II, Dinarello C., Jaffe E.A., Chess L.: Selfregulation of procoagulant events on the endothelial cell surface. J. Exp. Med. 162:1223-1235, 1985.
8. Nawroth P.P., Handley D., Esmon C.T., Stern D.: Interleukin 1 induces endothelial cell procoagulant while suppressing cell surface anticoagulant activity. Proc. Natl. Acad. Sci. USA 83:3460-3464, 1986.
9. Nawroth P.P., Stern D.M.: Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med. 163:740-745, 1986.
10. Stern D.M., Brett J., Harris K., Nawroth P.P.: Participation of endothelial cells in the protein C-protein S anticoagulant pathway. J. Cell Biol. 102:1971-1978, 1986.
11. Nawroth P.P., Bank I., Handley D., Cassimeris J., Chess L., Stern D.M.: Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J. Exp. Med. 163:1363-1375, 1986.
12. Nawroth P.P., Handley D.A., Matsueda G., deWaal R., Gerlach H., Blohm D., Stern. D.M.: Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth-A fibrosarcomas. J. Exp. Med. 168:637-647, 1988.
13. Brett J.G., Steinberg S.F., deGroot P.G., Nawroth P.P., Stern D.M.: Norepinephrine down-regulates the activity of protein S on endothelial cells. J. Cell. Biol. 106:2109-2119, 1988.
14. Brett J., Gerlach H., Nawroth P.P., Steinberg S., Godman G., Stern D.: Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J. Exp. Med. 169:1977-1991, 1989.
15. Zhang Y., Deng J., Luther Th., M. Müller, Ziegler R., Waldherr R., Stern D.M., Nawroth P.P.: Tissue Factor controls the balance of angiogenic and antiangiogenic properties of tumor cells. J. Clin. Invest. 94:1320-1327, 1994.
16. Fotsis Th., Zhang Y., Pepper M., Adlerscrews H., Montesano R., Nawroth P.P., Schweigerer L.: 2-Methoxyestradiol, an estrogen metabolite, inhibits angiogenesis and suppresses tumour growth. Nature 368:237-239, 1994.
17. Yan S.D., Yan S.F., Chen X., Fu J., Chen M., Kuppusumay P., Smith M.A., Perry G., Godman G.C., Nawroth P., Zweier J., Stern D.: Nonenzymatically glycated tau in alzheimers disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid-beta peptide. Nature Medicine 1:693-699, 1995.
18. Zhang Y., Deng Y., Wendt Th., Liliensiek B., Bierhaus A., Greten J., Wei H., Chen B., Hach-Wunderle V., Waldherr R., Ziegler R., Stern D.M., Männel D., Nawroth P.P.: Intravenous somatic gene transfer with antisense-tissue factor restores blood flow by reducing tumor necrosis factor induced tissue factor expression and fibrin deposition in mouse Meth-A sarcomas. J. Clin. Invest. 97:2213-2224, 1996.
19. Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D., Schmidt A.M.: RAGE and amyloid beta-peptide neurotoxicity in Alzheimers disease. Nature 382:685-691, 1996.
20. Zhang Y., Weiler-Guettler H., Jiang Chen, Wilhelm O., Deng Y., Qiu F., Nakagawa K., Klevesath M., Wilhelm S., Böhrer H., Nakagawa M., Graeff H., Martin E., Stern D.M., Rosenberg R., Ziegler R., Nawroth P.: Thrombomodulin modulates growth of tumor cells independent of its anticoagulant activity. J. Clin. Invest. 101:1301-1309, 1998.
21. Böhrer H., Qiu F., Zimmermann Th., Zhang Y., Bierhaus A., Ilmer Th., Männel D., Böttiger B.W., Stern D.M., Waldherr R., Saeger H.-D., Ziegler R., Martin E., Nawroth P.P.: Role of NFkB in the mortality of sepsis. J. Clin. Invest. 100:972-985, 1997.
22. 2Abe K., Shoji M., Chen J., Bierhaus A., Danave I., Micko C., Casper C., Dillehay D.L., Nawroth P.P., Rickles R.: Regulation of vascular endothelial cell growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc. Natl. Acad. Sci. USA 96:8663-8668, 1999.
23. Hofmann M. A., Drury S., Fu C., Wu Q., Taguchi A., Lu Y., Avila C., Kambham N., Slattery T., Beach D., McClary J., Nagashima M., Morser J., Bierhaus A., Neurath M., Nawroth P., Stern D., Schmidt A.M.: RAGE mediates a novel proinflammatory axis: The cell surface receptor for S100/calgranulin polypeptides. Cell 97:889-901, 1999.
24. Nawroth P.P., Häring H.-U.: Thrombomodulin and coronary heart disease (commentary). Lancet 353:1722-1723, 1999.
25. Liebibel U, Sommer U, Tomakidi P, Hilscher U, van den Heuvel L, Pirzer R, Hillmeiner J. Nawroth P, Kasperk Ch: Concerted action of androgens and mechanical strain shifts bone metabolism from high turnover into an osteoanabolic mode. J. Exp. Med. 196, 1387-1392, 2002.
26. Schneider J, Schäfer S, Lettgen B, Keiper T, Nawroth P.P, Dugi K. Siblings with hepatosplenomegaly and lipoprotein lipase deficiency. Lancet 360, 1150, 2002.
27. Bierhaus A, Wolf J, Andrassy M, Rohleder N, Humpert P M, Petrov D, Ferstel R, Wendt Th, Rudofsky G, Joswig M, Morcos M, Schwaninger M, McEwing B, Kirschbaum C, Nawroth PP: A mechanism converting psychosocial stress into mononuclear cell activation. Proc. Natl. Acad. Sci. USA 100, 1920-1925, 2003.
28. Hammes H-P, Du X, Edelstein D, Taguchi T, Matsumara T, Ju Q, Lin H, Bierhaus A, Nawroth PP, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M: Benfotiamine blocks three major pathways of hyperglycemic damage and prevent experimental diabetic retinopathy. Nature Medicine 9, 294-299, 2003.
29. Skaguchi T, Yan S.F, Yan S.D, Belov D, Rong L.L, Sousa M, Andrassy M, Marso S.P, Duda S, Arnold B, Liliensiek B, Nawroth P.P, Stern D.M, Schmidt AM, Naka Y: Central role of RAGE-dependent neointimal expansion in arterial resetenosis. J. Clin. Invest. 111, 959-972, 2003.
30. Deane R, Yan S.D, Submamaryan R.K, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin Ch, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt A.M, Armstrong D.L, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B: RAGE mediates amyloid-ß peptide transport across the blood brain barrier and accumulation in brain. Nature Medicine 9: 907-913, 2003.
31. Chavakis T, Bierhaus A, Al-Fakhari N, Schneider D, Witte S, Linn T, Nagashima M, Morser J, Arnold B, Preissner K.T, Nawroth PP: The pattern recognition receptor RAGE is a counterreceptor for leukocyte integrins. A novel pathway for inflammatory cell recruitment. J. Exp. Med. 198, 1507-1515, 2003.
32. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S, Plachky J, Gröne H-J, Kurschus FC, Schmidt A.M, Yan SD, Martin E, Schleicher E, Stern DM, Hämmerling G, Nawroth PP, Arnold B: Receptor for advanced glycation end products regulates sepsis but not the adaptive immune response. J. Clin. Invest. 113, 1641-1650, 2004.
33. Bierhaus A, Haslbeck K.-M, Humpert P, Liliensiek B, Dehmer Th, Morcos M, Sayed AR, Andrassy AM, Schiekofer S, Schneider JG, Schulz JB, Heuss D, Neundörfer B, Dierl S, Huber J, Tritschler H, Schmidt AM, Schwaninger M, Häring HU, Schleicher E, Kasper M, Stern DM, Arnold B, Nawroth PP: Loss of pain perception in diabetes is dependent on a receptor of the immunglobulin superfamily. J. Clin. Invest. 114, 1741-1751, 2004.
34. Zhou Z, Immel D, Xi C-X, Bierhaus A, Feng X, Mei L, Nawroth PP, Stern D.M, Xiong W-Ch: Regulation of osteoclast function and bone mass by RAGE. J. Exp. Med. 203, 1067-1080, 2006.
35. Orlova VV, Choi EY, Xie C, Chavakis E, Bierhaus A, Ihanus E, Ballantyne CM, Gahmberg CG, Bianchi ME, Nawroth PP, Chavakis T. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J. 26:1129-39, 2007.
36. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8:487-96, 2007.
37. Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J, Corat MA, Zeier M, Blessing E, Oh J, Gerlitz B, Berg DT, Grinnell BW, Chavakis T, Esmon CT, Weiler H, Bierhaus A, Nawroth PP. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nature Medicine 13:1349-58, 2007.
38. Gebhardt C, Riehl A, Durchdewald M, Németh J, Fürstenberger G, Müller-Decker K, Enk A, Arnold B, Bierhaus A, Nawroth PP, Hess J, Angel P. RAGE signaling sustains inflammation and promotes tumor development. J. Exp. Med. 205:275-85, 2008.
39. Muhammad S, Barakat W, Stoyanov S, Murikinati S, Yang H, Tracey KJ, Nawroth PP, Bierhaus A, Schwaninger M: The HMGB1 receptor RAGE mediates ischemic brain damage. J. Neuroscience 28: 2023-31, 2008.
40. Rauschenberger K, Schöler K, Sass JO, Sauer S, Djuric Z, Rumig C, Wolf NI, Okun JG, Kölker S, Schwarz H, Fischer C, Grziwa B, Runz H, Nümann A, Shafqat N, Kavanagh KL, Hämmerling G, Wanders RJ, Shield JP, Wendel U, Stern D, Nawroth P, Hoffmann GF, Bartram CR, Arnold B, Bierhaus A, Oppermann U, Steinbeisser H, Zschocke J. A non-enzymatic function of 17beta-hydroxysteroid dehydrogenase type 10 is required for mitochondrial integrity and cell survival. EMBO Mol. Med. 2:51-62, 2010.
41. Kulozik P, Jones A, Mattijssen F, Rose AJ, Reimann A, Strzoda D, Kleinsorg S, Raupp C, Kleinschmidt J, Müller-Decker K, Wahli W, Sticht C, Gretz N, von Loeffelholz C, Stockmann M, Pfeiffer A, Stöhr S, Dallinga-Thie GM, Nawroth PP, Berriel Diaz M, Herzig S. Hepatic deficiency in transcriptional cofactor TBL1 promotes liver steatosis and hypertriglyceridemia. Cell Metab. 13:389-400, 2011.
42. Kashif M, Hellwig A, Kolleker A, Shahzad K, Wang H, Lang S, Wolter J, Thati M, Vinnikov I, Bierhaus A, Nawroth PP, Isermann B. p45NF-E2 represses Gcm1 in trophoblast cells to regulate syncytium formation, placental vascularization and embryonic growth. Development 138:2235-47, 2011.
43. Meissburger B, Ukropec J, Roeder E, Beaton N, Geiger M, Teupser D, Civan B, Langhans W, Nawroth PP, Gasperikova D, Rudofsky G, Wolfrum C. Adipogenesis and insulin sensitivity in obesity are regulated by retinoid-related orphan receptor gamma. EMBO Mol. Med. 3:637-51, 2011.
44. Bierhaus A, Fleming T, Stoyanov S, Leffler A, Babes A, Neacsu C, Sauer SK, Eberhardt M, Schnölzer M, Lasitschka F, Neuhuber WL, Kichko TI, Konrade I, Elvert R, Mier W, Pirags V, Lukic IK, Morcos M, Dehmer T, Rabbani N, Thornalley PJ, Edelstein D, Nau C, Forbes J, Humpert PM, Schwaninger M, Ziegler D, Stern DM, Cooper ME, Haberkorn U, Brownlee M, Reeh PW, Nawroth PP. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nature Medicine 18:926-33, 2012.
45. Bock F, Shahzad K, Wang H, Stoyanov S, Wolter J, Dong W, Pelicci PG, Kashif M, Ranjan S, Schmidt S, Ritzel R, Schwenger V, Reymann KG, Esmon CT, Madhusudhan T, Nawroth PP, Isermann B. Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc. Proc. Natl. Acad. Sci. USA 110:648-53, 2013.

Das einjährige, verhaltenstherapeutisch basierte Gewichtsreduktionsprogramm Optifast®52 eignet sich aufgrund seines standardisierten Therapiekonzeptes sehr gut für wissenschaftliche Auswertungen. So können anhand verschlüsselter Daten des Optifast-Patientenkollektivs z.B. Fragen bezüglich Gewichtsreduktion und Gewichtsstabilisierung untersucht werden. Folgende Studien wurden im Rahmen des Optifast-Programms am Uniklinikum Heidelberg bereits durchgeführt:  

Publikationen Optifast

Winkler JK, Woehning A, Schultz JH et al. Taq1A polymorphism in dopamine D2 receptor gene complicates weight maintenance in younger obese patients. Nutrition 2012;28(10):996-1001

Woehning A, Schultz JH, Roeder E et al. The A-allele of the common FTO gene variant rs9939609 complicates weight maintenance in severe obese patients. 
Int J Obes 2013;37(1):135-139

Winkler JK, Schultz JH, Woehning A et al. Effectiveness of a low-calorie weight loss program in moderately and severely obese patients. Obesity Facts 2013;6(5):469-480

Wallmeier D, Woehning A, Winkler JK et al. Genetic modulation of the serotonergic pathway: influence on weight reduction and weight maintenance. Genes Nutr 2013;8:601-610